ProKidney Corp. Class A Ordinary Shares
PROKProKidney Corp. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for kidney diseases. The company's offerings aim to address unmet medical needs in the nephrology space, with a focus on improving patient outcomes through novel treatments.
Company News
ProKidney presented Phase 2 trial results showing rilparencel potentially slows chronic kidney disease progression in diabetic patients, with statistically significant improvements in estimated glomerular filtration rate (eGFR) slope and no serious adverse events.
Top-ranked stocks Wingstop (WING), Burlington Stores (BURL) and Prokidney CP (PROK) are likely to beat on the bottom line in their upcoming releases.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are...
Two factors led to the stock's slide on Thursday.
